Journal Mobile Options
Table of Contents
Vol. 59, No. 4, 2000
Issue release date: November 2000
Oncology 2000;59:302–309

Cytoplasmic Beta-Catenin Accumulation as a Predictor of Hematogenous Metastasis in Human Colorectal Cancer

Maruyama K. · Ochiai A. · Akimoto S. · Nakamura S. · Baba S. · Moriya Y. · Hirohashi S.
aPathology Division, National Cancer Center Research Institute, Tokyo, bSecond Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, cSurgery Division, National Cancer Center Hospital, Tokyo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The membranous, cytoplasmic and nuclear levels of beta-catenin were evaluated immunohistochemically in archival tissue specimens from 96 Japanese patients with primary colorectal carcinoma who had undergone surgery. The relationships between beta-catenin and clinicopathological variables were analyzed statistically. Reduced beta-catenin immunoreactivity in the cell membranes of cancer cells was found in 70% of the tumors, and cytoplasmic and nuclear accumulation of beta-catenin were found in 68 and 66% of tumors, respectively. Significant correlations between cytoplasmic beta-catenin accumulation and the depth of invasion, venous invasion and focal dedifferentiation were observed. Cytoplasmic beta-catenin accumulation was also found to be a useful predictor of hematogenous metastasis (hazard ratio = 8.94, p = 0.054), though neither a reduced cell membrane level nor nuclear accumulation of beta-catenin correlated with metastasis.

Copyright © 2000 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Behrens J, Mareel MM, Van Roy FM, Birchmeier W: Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-metiated cell-cell adhesion. J Cell Biol 1999;108:2435–2447.
  2. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173–185.
  3. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107–119.
  4. Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333–339.
  5. Ozawa M, Baribault H, Kemler R: The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989;8:1711–1717.
  6. Nagafuchi A, Takeichi M: Transmembrane control of cadherin-mediated cell adhesion: A 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1989;1:37–44.

    External Resources

  7. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996;382:638–642.
  8. Su LK, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 1993;262:1734–1737.
  9. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P: Association of the APC gene product with beta-catenin. Science 1993;262:1731–1734.
  10. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787–1790.
  11. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines (see comments). Science 1997;275:1790–1792.
  12. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P: Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995;92:3046–3050.
  13. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y: Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998;58:1021–1026.
  14. Porfiri E, Rubinfeld B, Albert I, Hovanes K, Waterman M, Polakis P: Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin. Oncogene 1997;15:2833–2839.

    External Resources

  15. Kemler R: From cadherins to catenins: Cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317–321.
  16. Barth AI, Nathke IS, Nelson WJ: Cadherins, catenins and APC protein: Interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997;9:683–690.
  17. Ben-Ze’ev A, Geiger B: Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol 1998;10:629–639.
  18. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC pathway (see comments). Science 1998;281:1509–1512.
  19. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C: Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96:1603–1608.
  20. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422–426.
  21. Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S: Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 1996;56:2213–2217.
  22. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ: Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: Relationship with patient survival. Gastroenterology 1997;112:46–54.
  23. Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, Inoue M, Monden T, Ito F, Monden M: Beta-catenin expression in human cancers. Am J Pathol 1996;148:39–46.
  24. Hashizume R, Koizumi H, Ihara A, Ohta T, Uchikoshi T: Expression of beta-catenin in normal breast tissue and breast carcinoma: A comparative study with epithelial cadherin and alpha-catenin. Histopathology 1996;29:139–146.
  25. Japanese Society for Cancer of the Colon and Rectum: Japanese Classification of Colorectal Carcinoma, first English edition. Tokyo, Kanehara, 1997.
  26. Akimoto S, Ochiai A, Inomata M, Hirohashi S: Expression of cadherin-catenin cell adhesion molecules, phosphorylated tyrosine residues and growth factor receptor-tyrosine kinases in gastric cancers. Jpn J Cancer Res 1998;89:829–836.

    External Resources

  27. Ochiai A, Akimoto S, Shimoyama Y, Nagafuchi A, Tsukita S, Hirohashi S: Frequent loss of alpha catenin expression in scirrhous carcinomas with scattered cell growth. Jpn J Cancer Res 1994;85:266–273.
  28. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
  29. Cox DR: Regression models and life tables. J Stat Soc 1972;34:187–220.
  30. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159–170.
  31. Gunther K, Brabletz T, Kraus C, Dworak O, Reymond MA, Jung A, Hohenberger W, Kirchner T, Kockerling F, Ballhausen WG: Predictive value of nuclear beta-catenin expression for the occurrence of distant metastases in rectal cancer. Dis Colon Rectum 1998;41:1256–1261.

    External Resources

  32. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T: Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 1998;194:701–703.
  33. Ilyas M, Tomlinson IP: The interactions of APC, E-cadherin and beta-catenin in tumour development and progression. J Pathol 1997;182:128–137.
  34. Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyama T, Hirohashi S: c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun 1994;205:73–78.
  35. Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S: c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 1995;208:1067–1072.
  36. Hoschuetzky H, Aberle H, Kemler R: Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994;127:1375–1380.
  37. Shibata T, Ochiai A, Kanai Y, Akimoto S, Goth M, Yasui N, Machinami R, Hirohashi S: Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 1996;13:883–889.

    External Resources

  38. Nakamura S, Suzuki S, Baba S: Resection of liver metastases of colorectal carcinoma. World J Surg 1997;21:741–747.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50